Documente Academic
Documente Profesional
Documente Cultură
INTRODUCTION
LOWER EXTREMITY PERIPHERAL
ARTERIAL DISEASE (PAD)
Affects 10 million people in the U.S.
About 4.3 % of everyone > 40 years old
About 14.5% of people > 70 years old
2 X increased incidence with each decade of life
100,000 patients undergo some form of
revascularization each year
CLASSIFICATION OF LOWER
EXTREMITY PAD
Intermittent Claudication
Critical Limb Ischemia (CLI)
Ischemia pain at rest
Ischemia ulceration
Gangrene
Infection
INTERMITTENT CLAUDICAITON
Most common symptom of PAD
Extertional leg pain
Life-style limiting to disabling
Generally one anatomic segment of arterial occlusion
Moderate limb ischemia
33% have treatable CAD
<1% per year risk of amputation
>3% - 5% per year risk of cardiac death
DIFFERENTIAL DIAGNOSIS
OF LEG PAIN
Spinal stenosis
Nerve root compression
Peripheral neuropathy
Degenerative joint disease
Bakers cyst
Venous claudication
Chronic compartment syndrome
Cardiac disease
Hypertension
Diabetes mellitus
Hypercaogulability
Hyperhomocysteinemia
Renal insufficiency
VASCULAR ASSESMENT IN
PATIENTS WITH PAD
History and physical examination
Doppler examination
Vascular laboratory studies
CT ateriography
MR ateriography
Invasive contrast ateriography
VASCULAR LOBORATORY
ASSESMENT OF PAD
Presence and direction of arterial blood flow
Character or quality of blood flow (Doppler waveforms)
Precise arterial systolic blood pressure measurement
Ankle / Brachial Index (ABI) relative severity of arterial
insufficiency
Qualitative anatomy of PAD (segmental arterial pressures)
Serial or comparative arterial assessments
Arterial Duplex (B-mode ultrasound and Doppler flow
velocities)
INTERPRETATION OF ANKLE /
BRACHIAL INDICIES (ABIS)
Normal
Mild limb ischemia
Moderate limb ischemia
Severe limb ischemia
Non-compressible
Minimal symptoms
Claudication
Rest pain, Tissue loss
CHARACTERISTICS OF
INTERMETTEMNT CLAUDICATION
Exercise induced pain symptoms
Absent femoral and/or pedal pulses
ABIs 0.4 - 0.7 range indicating moderate limb ischemia
One level of arterial occlusion
Aorto-iliac (LeRiche Syndrome) hip or calf pain,
vasogenic
impotence
SFA occlusion calf pain
Medical treatment preferred
Often successfully treated with endovascular techniques
Surgery reserved for sever symptoms in good risk patients
CHARACTERISTICS OF CRITICAL
LIMB ISCHEMIA
Ischemia pain at rest or tissue loss
Absent femoral and/or pedal pulses
Distal rubor, ulceration, gangrene, and/or infection (risk of
amputation)
ABIS < 0.4 indication severe limb ischemia
Two levels of arterial occlusion (unless diabetic)
Medical treatment alone is usually ineffective
Sometimes improved with endovascular techniques
Surgical bypass is usually required
TREATMENT OF AORTO-ILIAC
OCCLUSIVE DISEASE
Aorto-Femoral Bypass (AFB)
3-5% M&M
90% 5 year patency
Aortic endarterectomy
3-5% M&M
80% 5 year patency
Extra-anatomic Bypass
1-2% M&M
60% 5 year patency
Iliac balloon angioplasty
< 1% M&M
Claudication
Stenosis
65% 5 year patency
Occlusion
54% 5 year patency
Critical ischemia Stenosis
53% 5 year patency
Occlusion
45% 5 year patency
Iliac stent
<1% M&M
Claudication
Stenosis
77% 5 year patency
Occlusion
61% 5 year patency
Critical ischemia Stenosis
57% 5 year patency
Occlusion
51% 5 year patency
TREATMENT OF INFRA-INGUAL
OCCLUSIVE DISEASE
Ak Fem-pop bypass
1-2% M&M
GSV graft
69% 5 year patency
PTFE graft 60% 5 year patency
BK Fem-pop bypass
1-2% M&M
GSV graft
77% 5 year patency
PTFE
40% 5 year patency
SFA-pop balloon angioplasty < 1% M&M
Claudication
Stenosis
53% 5 year patency
Occlusion
36% 5 year patency
Critical ischemia Stenosis 31% 5 year patency
Occlusion
16% 5 year patency
PROBABILITY OF BYPASS
FAILURE BY CO-MORBIDITY
Impaired ambulation
Distal PAD
ESRD
Gangrene
Hyperlipidemia
58%
46%
35%
34%
11%
CONCLUSION
The diagnosis and treatment of PAD is not just a vascular surgical
problem.
Risk factor modification (Vascular Medicine) will become an
increasingly important adjunct to all surgical and endovascular
therapies.
Primary care providers will have a greater role in the treatment of PAD.
Traditional measures of procedural treatment success such as morbidity
and vessel patency are no longer a sufficient means of evaluating
success.
New endovascular technologies have greatly broadened the number of
treatment options available and will continue to evolve in the near
future.